Le Lézard
Classified in: Science and technology, Covid-19 virus
Subjects: Contract/Agreement, Product/Service

ExtraHop Helps MAPCO Set Their Sites on the Road Ahead


ExtraHop, the leader in cloud-native network detection and response, today announced that MAPCO is using ExtraHop® Reveal(x)tm to ensure the secure delivery of cloud applications as the company scales in the cloud to meet the demands of an expanding company.

MAPCO operates a growing network of convenience store locations across the southeastern United States. The company prides itself on delivering an exceptional customer experience, from quality products and services to its signature coffee. In 2019, MAPCO began laying the groundwork for further expansion. To rapidly scale up IT resources on-demand to support both in-store and operations-focused applications, the team at MAPCO turned to Amazon Web Services (AWS). However, the move to AWS also introduced new complexity when it came to visibility across their entire environment.

"ExtraHop was awesome because it was an all-in-one solution," said Ricardo Bauza, Sr. Network Engineer at MAPCO. "Our team didn't have to learn a new tool, and we had information about the health and security of all of our applications in one place. With the built-in option for traffic mirroring in AWS, implementing Reveal(x) in the cloud was easy?it took less than 30 minutes."

In March 2020 when COVID-19 started to spread in the U.S., MAPCO, like many organizations, needed to transition a large portion of its headquarters employees to secure remote work. MAPCO used Reveal(x) to gain visibility during the urgent project and were successfully able to move 300 people to using VPN in less than three days. They were also able to verify the security of those configurations, and monitor to make sure remote employees could access what they needed to stay productive.

A detailed case study of the implementation of ExtraHop Reveal(x) at MAPCO is available here.

About ExtraHop

ExtraHop delivers cloud-native network detection and response to secure the hybrid enterprise. Our breakthrough approach applies advanced machine learning to all cloud and network traffic to provide complete visibility, real-time threat detection, and intelligent response. With this approach, we give the world's leading enterprises including The Home Depot, Credit Suisse, Liberty Global and Caesars Entertainment the perspective they need to rise above the noise to detect threats, ensure the availability of critical applications, and secure their investment in cloud. To experience the power of ExtraHop, explore our interactive online demo or connect with us on LinkedIn and Twitter.

© 2020 ExtraHop Networks, Inc., Reveal(x), Reveal(x) 360, Reveal(x) Enterprise, and ExtraHop are registered trademarks or marks of ExtraHop Networks, Inc.


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: